T&L Co

T&L Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of T&L Co (340570.KQ) as of Oct 30, 2026 is -2.47. In the previous year, Net Debt to Free Cash Flow Ratio was -2.67 — a change of -7.20% (higher).

Net Debt/FCF

-2.47

YoY

-7.20%

Last updated:

Net Debt to Free Cash Flow Ratio of T&L Co is 2024 -2.47 . Net Debt to Free Cash Flow Ratio of T&L Co was 2023 -2.67 . It decreases by -7.20% higher compared to the previous year.

The T&L Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.44 KRW
Jan 1, 2019
-0.43 KRW
Jan 1, 2020
-5.43 KRW
Jan 1, 2021
-12.16 KRW
Jan 1, 2022
52.72 KRW
Jan 1, 2023
-2.67 KRW
Jan 1, 2024
-2.47 KRW
The T&L Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-2.47-7.20%
-2.67-105.06%
52.72-533.35%
-12.16+124.17%
-5.43+1,148.07%
-0.43-197.81%
0.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

T&L Co Stock analysis

What does T&L Co do? T&L Co., Ltd. generates revenue through the sale of medical polymer material products including wound treatment materials like hydrocolloids, foams, and hydrogels, which are essential for wound healing. The company also offers orthopedic fixing materials such as casts and splints for fracture treatment, alongside structural adhesives and water repellents. Domestic and international markets, particularly the United States, Germany, China, and Dubai, purchase these products. The firm's product portfolio targets healthcare providers and medical facilities requiring specialized materials for patient care. T&L Co., Ltd. focuses on developing medical polymer materials that serve specific clinical needs, with wound treatment materials being a key segment. Orthopedic fixing materials are sold to hospitals and clinics for fracture management, while structural adhesives and water repellents cater to industrial applications. The company's international presence in the United States, Germany, China, and Dubai supports its market diversification strategy. The firm's revenue streams are derived from the consistent demand for medical polymer products in wound care, orthopedic solutions, and industrial adhesives. Products such as hydrocolloids, foams, and hydrogels are sold to healthcare providers, while orthopedic devices like casts and splints are distributed to medical institutions. Structural adhesives and water repellents are marketed to industrial clients in key global markets. T&L Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about T&L Co stock

Net Debt to Free Cash Flow Ratio of T&L Co is -2.47 in 2024.

Net Debt to Free Cash Flow Ratio of T&L Co changed from -2.67 to -2.47, representing a -7.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio T&L Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's T&L Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — T&L Co

All Key Metrics — T&L Co